Australian HealthTech Market: 2026 State of Play & Outlook to 2028

Why It Matters

The combination of rapid capital inflows, government backing, and scaling AI‑driven solutions positions Australia as a high‑growth, investment‑ready health‑tech hub for global players.

Key Takeaways

• Digital health market to hit $31.1 bn USD by 2034, ~15% CAGR
• FY 2026 fundraising reached $275 m USD, >100% YoY increase
• Pro Medicus revenue up 28%, EBIT margin 73%, cash $146 m USD
• Government allocated $2.5 bn USD to digital‑health infrastructure
• Clinical AI moves from pilot to production, driving M&A premiums

Pulse Analysis

Australia’s health‑tech ecosystem is transitioning from a niche segment to a cornerstone of the national economy. The digital‑health market, now $8.9 bn USD, is set to triple by 2034, driven by AI‑enabled diagnostics, remote patient monitoring, and a rapidly ageing population. Telehealth alone is forecast to climb from $542 m USD to $2.6 bn USD, reflecting persistent demand for rural access and chronic‑disease management. This growth is underpinned by a robust pipeline of listed players—Pro Medicus, 4DMedical, and ResMed—whose strong margins and cash positions make them attractive acquisition targets.

Capital markets have responded with vigor. Private fundraising surged to $275 m USD in CY25, led by specialist VC funds focusing on AI‑powered diagnostics and RPM solutions. Meanwhile, private‑equity deals topped $617 m AUD (≈$408 m USD), with notable transactions in diagnostic imaging and aged‑care software. Government spending adds another layer of confidence, with roughly $2.5 bn USD earmarked for My Health Record upgrades, Medicare digitisation, and aged‑care ICT. These funds not only de‑risk early‑stage ventures but also create a captive customer base that accelerates product adoption.

For international investors, the upside is twofold. First, the weak Australian dollar (≈0.66 USD) offers a valuation discount relative to comparable US and European markets, making strategic buyouts financially compelling. Second, the sector’s shift toward production‑grade clinical AI—exemplified by Harrison.ai and Heidi Health—creates premium‑multiple opportunities, especially in diagnostics and documentation automation. As interoperability standards like FHIR become mandatory, legacy vendors will face displacement, opening further consolidation pathways for well‑capitalised entrants seeking to build end‑to‑end digital‑health platforms across the ANZ region.